Table 3.
Compilation of results from the six experimental designs for the encapsulation of articaine in nanostructured lipid carriers.
| Formulation | Size (nm) - range of variation | Significant variables for size | PDI - range of variation | Significant variables for PDI | ZP |mV| - range of variation | Significant variables for ZP | |||
|---|---|---|---|---|---|---|---|---|---|
| Pos | Neg | Pos | Neg | Pos | Neg | ||||
| NLC-CP1-A | 182.7–303.2 | – | P68 | 0.160–0.188 | – | P68, ATC | 31.9–46.3 | ATC | – |
| NLC-CP2-A | 237.6–585.0 | – | T80 | 0.095–0.230 | T80 | TL, ATC | 32.1–47.0 | ATC | – |
| NLC-CO1-A | 223.7–364.8 | TL | P68 | 0.170–0.329 | – | P68, ATC | 31.7–49.1 | ATC | – |
| NLC-CO2-A | 187.6–282.0 | TL | T80, ATC | 0.147–0.210 | – | ATC | 27.5–41.0 | ATC | – |
| NLC-OO1-A | 216.8–322.0 | ATC | P68 | 0.160–0.231 | ATC | P68 | 29.3–47.8 | ATC | – |
| NLC-OO2-A | 204.6–302.1 | TL | T80 | 0.080–0.244 | – | ATC | 32.5–51.9 | ATC | – |
Significant variables with positive (Pos) and negative (Neg) effects. TL total lipids, P68 Pluronic F-68, T80 Tween 80, ATC articaine.